The novel alkylating prodrug J1: Diagnosis directed activity profile ex vivo and combination analyses in vitro

Investigational New Drugs

Volumn 26, Issue 3, 2008, Pages 195-204

  Wickström, Malin ^a   Haglund, Caroline ^a   Lindman, Henrik ^a   Nygren, Peter ^a   Larsson, Rolf ^a   Gullbo, Joachim ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CalcuSyn; Combination; Diagnosis; J1; Melphalan; Prodrug

Indexed keywords

'J1'; ALKYLATING AGENT; BORTEZOMIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; MELPHALANYL 4 FLUOROPHENYLALANYL ETHYL ESTER; PREDNISOLONE; PRODRUG; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; CELL LINE; CYTOFLUOROMETRY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG POTENCY; DRUG POTENTIATION; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLUOROMETRY; HUMANS; MELPHALAN; NEOPLASMS; PRODRUGS;

EID: 42549086712     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9092-1     Document Type: Article

References (37)

1. Furner RL, Brown RK (1980) L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep 64:559-74
2. Teicher BA (1997) (405-418) Antitumor alkylating agents. In: De Vita Hellman Rodenberg VTSSA (ed) Cancer principals and practice of oncology. Lippincott-Raven, Philadelphia, USA
3. Jones RB (2002) Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res 112:305-322
4. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC Jr, Gajewski JL, Champlin RE (2001) High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82:420-426
5. Demirer T, Uysal VA, Ayli M, Genc Y, Ilhan O, Koc H, Dagli M, Arat M, Gunel N, Fen T, Dincer S, Ustael N, Yildiz M, Ustun T, Seyrek E, Ozet G, Muftuoglu O, Akan H (2003) High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Bone Marrow Transplant 31:755-761
6. Gullbo J, Dhar S, Luthman K, Ehrsson H, Lewensohn R, Nygren P, Larsson R (2003) Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L- sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan. Anti-cancer Drugs 14:617-624
7. Gullbo J, Tullberg M, Vabeno J, Ehrsson H, Lewensohn R, Nygren P, Larsson R, Luthman K (2003) Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives. Oncol Res 14:113-132
8. Gullbo J, Lindhagen E, Bashir-Hassan S, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, De La Torre M, Luthman K, Larsson R (2004) Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drugs 22:411-420
9. Wickström M, Johnsen JI, Ponthan F, Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson K, Lewensohn R, Kogner P, Larsson R, Gullbo J (2007) The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther 6:2409-2417
10. Gullbo J, Wickstrom M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R (2003) Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target 11:355-363
11. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM, Hoekman K (2002) Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 8:3747-3754
12. Suganuma T, Ino K, Shibata K, Nomura S, Kajiyama H, Kikkawa F, Tsuruoka N, Mizutani S (2004) Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor. Lab Invest 84:639-648
13. Martinez JM, Prieto I, Ramirez MJ, Cueva C, Alba F, Ramirez M (1999) Aminopeptidase activities in breast cancer tissue. Clin Chem 45:1797-1802
14. Bosanquet AG, Bell PB (2004) Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells. J Exp Ther Oncol 4:145-154
15. Fridborg H, Jonsson E, Nygren P, Larsson R (1999) Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 35:424-432
16. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
17. Frickhofen N, Berdel WE, Opri F, Haas R, Schneeweiss A, Sandherr M, Kuhn W, Hossfeld DK, Thomssen C, Heimpel H, Kreienberg R, Hinke A, Mobus V (2006) Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. Bone Marrow Transplant 38:493-499
18. Larsson R, Kristensen J, Sandberg C, Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50:177-185
19. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P (1994) Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 54:163-170
20. Nygren P, Kristensen J, Jonsson B, Sundstrom C, Lonnerholm G, Kreuger A, Larsson R (1992) Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 6:1121-1128
21. Rickardson L, Fryknas M, Haglund C, Lovborg H, Nygren P, Gustafsson MG, Isaksson A, Larsson R (2006) Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 58:749-758
22. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL, Gatter KC (1994) Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 47:43-47
23. Pulido-Cejudo G, Miranda H, El Abdaimi K, Wang C, Kar B, Medina Acevedo J, Cardenas JM, Sarti Gutierrez E, Perez Palacios G (2004) A monoclonal antibody driven biodiagnostic system for the quantitative screening of breast cancer. Biotechnol Lett 26:1335-1339
24. Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M (2006) Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 12:3971-3978
25. Surowiak P, Drag M, Materna V, Suchocki S, Grzywa R, Spaczynski M, Dietel M, Oleksyszyn J, Zabel M, Lage H (2006) Expression of aminopeptidase N/CD13 in human ovarian cancers. Int J Gynecol Cancer 16:1783-1788
26. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F (2005) Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol 98:11-18
27. Yamashita M, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer 120:2243-2250
28. Ishii K, Usui S, Yamamoto H, Sugimura Y, Tatematsu M, Hirano K (2001) Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J Biochem (Tokyo) 129:253-258
29. Varona A, Blanco L, Lopez JI, Gil J, Agirregoitia E, Irazusta J, Larrinaga G (2007) Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 292:F780-F788
30. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, Laurberg S, Sorensen FB, Hagemann R, Orntoft TF (2002) Gene expression in colorectal cancer. Cancer Res 62:4352-4363
31. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y, Miyake M (2002) Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 122:376-386
32. Kawamura J, Shimada Y, Kitaichi H, Komoto I, Hashimoto Y, Kaganoi J, Miyake M, Yamasaki S, Kondo K, Imamura M (2007) Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma. Hepatogastroenterology 54:36-40
33. Buzdar AU, Legha SS, Blumenschein GR, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Fraschini G, Bodey GP (1982) Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer 49:1767-1770
34. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734-741
35. Hirota H, Gosky D, Berger NA, Chatterjee S (2002) Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity. Int J Oncol 20:311-318
36. Valteau-Couanet D, Vassal G, Pondarre C, Bonnay M, Benhamou E, Couanet D, Plantaz D, Hartmann O (1996) Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. Bone Marrow Transplant 17:485-489
37. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937-944